Wells Fargo & Company Increases Edwards Lifesciences (NYSE:EW) Price Target to $100.00

Edwards Lifesciences (NYSE:EW) had its target price lifted by analysts at Wells Fargo & Company from $96.00 to $100.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the medical research company’s stock. Wells Fargo & Company‘s target price points to a potential upside of 30.91% from the company’s previous close.

Several other equities analysts have also recently issued reports on EW. National Bank Financial set a $92.00 price objective on shares of Edwards Lifesciences in a research note on Friday, October 31st. Jefferies Financial Group set a $98.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Wednesday, October 29th. BTIG Research reaffirmed a “buy” rating and issued a $103.00 price target on shares of Edwards Lifesciences in a report on Wednesday. Raymond James Financial raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective for the company in a research note on Monday, November 3rd. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $96.14.

Edwards Lifesciences Stock Down 3.7%

EW opened at $76.39 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. The company has a market capitalization of $44.33 billion, a PE ratio of 41.74, a P/E/G ratio of 3.03 and a beta of 0.94. The stock’s fifty day moving average is $83.55 and its 200-day moving average is $81.10. Edwards Lifesciences has a one year low of $65.94 and a one year high of $87.89.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). The firm had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities analysts predict that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insider Activity

In related news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. This represents a 4.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total value of $650,419.00. Following the sale, the chief financial officer owned 39,898 shares of the company’s stock, valued at $3,370,184.06. The trade was a 16.18% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 43,804 shares of company stock worth $3,699,082 over the last quarter. Corporate insiders own 1.29% of the company’s stock.

Institutional Trading of Edwards Lifesciences

A number of hedge funds have recently made changes to their positions in the stock. Advisors Asset Management Inc. grew its position in Edwards Lifesciences by 53.7% during the fourth quarter. Advisors Asset Management Inc. now owns 27,481 shares of the medical research company’s stock valued at $2,343,000 after purchasing an additional 9,598 shares in the last quarter. CI Investments Inc. boosted its stake in shares of Edwards Lifesciences by 5.6% during the 4th quarter. CI Investments Inc. now owns 16,994 shares of the medical research company’s stock valued at $1,449,000 after buying an additional 896 shares during the period. Johnson Financial Group Inc. grew its holdings in shares of Edwards Lifesciences by 36.0% during the 4th quarter. Johnson Financial Group Inc. now owns 1,799 shares of the medical research company’s stock valued at $153,000 after acquiring an additional 476 shares in the last quarter. Callan Family Office LLC increased its stake in shares of Edwards Lifesciences by 44.8% in the fourth quarter. Callan Family Office LLC now owns 54,906 shares of the medical research company’s stock worth $4,681,000 after acquiring an additional 17,000 shares during the last quarter. Finally, Financial Engines Advisors L.L.C. acquired a new position in Edwards Lifesciences in the 4th quarter worth about $206,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Key Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Analyst upgrades and reiterated buys lift longer‑term outlook — Wells Fargo raised its price target to $100 and moved to “overweight,” while BTIG and several other firms reiterated Buy ratings with ~$103 targets, supporting upside expectations. Article Title
• Positive Sentiment: Strong revenue growth and TAVR momentum highlighted on the earnings call — Management emphasized sustained Transcatheter Aortic Valve Replacement (TAVR) and other structural‑heart growth drivers; the company is leaning into growth after the quarter. Article Title
• Positive Sentiment: Options/contrarian take: some traders see the post‑earnings weakness as a buying opportunity — commentary suggests cleared uncertainty after results could support a tactical bullish trade. Article Title
• Neutral Sentiment: Mixed earnings print — Q4 revenue topped expectations and grew year‑over‑year, but EPS missed estimates. Revenue strength supports the growth narrative, while the EPS shortfall creates near‑term uncertainty. Article Title
• Neutral Sentiment: Sector context — Comparative coverage of healthcare earnings (AstraZeneca vs. Edwards vs. Zimmer Biomet) highlights macro/peer performance but is not specific to EW’s fundamentals. Article Title
• Negative Sentiment: Shareholder‑rights notice from Halper Sadeh LLC adds legal/uncertainty risk — a public call encouraging shareholders to contact the firm can prompt selling or increase perceived governance risk. Article Title

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.